Abstract
Clinical trials have shown promising results for adjuvant immunotherapy in resected stage III-IV melanoma patients, but real-life data are scarce. Data on efficacy and quality of life (QoL) during anti-PD-1 adjuvant therapy from a complete national cohort of melanoma patients may support treatment choices and help patient guidance.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
